Jeffrey Z. Mann, President, Pharm Svc&Prod Management, CLO at Embecta Corp. (EMBC), bought 20,000 shares at $4.99 ($100K) on 2026-08-12, disclosed to the SEC on 2026-08-13.
C-suite insider Jeffrey Mann purchased $99,800 of EMBC at $4.99, marking the largest purchase of his career. This move is significant as the stock trades near its 52-week low following a recent earnings beat.
EMBC is down 36.94% over the past year and is currently trading 43.47% below its 52-week high of $15.55, though it sits just 0.23% above its 52-week low of $8.77.
Catalysts include the Q3 2026 earnings call on August 8, the completion of the Owen Mumford acquisition on May 18, and the largest career purchase by C-suite insider Jeffrey Mann.
The stock faces significant headwinds with 14.18% of the float sold short and a recent downgrade to an Underperform rating by Bank of America with a $3 price target.
Negative factors outweigh the positive ones.
| Filing → |